Assuming that employing separate blots for total and phosphor‐4EBP1 provides an accurate readout of mTORC1 activity, we find that specific phytocannabinoids reduce mTORC1 signalling in immune cells (PBMCs), which is elevated during the proinflammatory activation of these cells (Gao et al., 2015) and therefore, our findings provide insight into a potential novel cellular target for phytocannabinoids in immune cells that may relate to MS treatment. Here, EIF4EBP1 is linked to myeloid sarcoma.